{"filing":{"accession_number":"0001493152-26-030342","cik":"0001582554","ticker":"MTNB","company_name":"Matinas BioPharma Holdings, Inc.","form":"8-K","filing_date":"2026-06-26","report_date":null,"primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1582554/000149315226030342/form8-k.htm"},"events":[{"id":14355,"run_id":12780,"accession_number":"0001493152-26-030342","anchor_item_number":null,"event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"summary":"The filing discloses that Matinas BioPharma received notice on June 24, 2026 from NYSE American of non-compliance with continued listing standards under Sections 1003(a)(ii) and 1003(a)(iii) of the NYSE American Company Guide, citing stockholders' equity of $3.02 million (below the $4.0 million minimum) and losses in five consecutive fiscal years. While the company's plan to regain compliance was accepted with a deadline of October 2, 2027, the filing explicitly warns that \"if the Company does not regain compliance...then NYSE American staff may initiate delisting proceedings as appropriate.\" This is a material delisting risk event that would significantly affect investor assessment of the registrant's continued listing status.","company_name":"Matinas BioPharma Holdings, Inc.","ticker":"MTNB","filing_date":"2026-06-26","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":11750,"accession_number":"0001493152-26-030342","item_number":null,"item_title":null,"event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"reasoning":"The filing discloses that Matinas BioPharma received notice on June 24, 2026 from NYSE American of non-compliance with continued listing standards under Sections 1003(a)(ii) and 1003(a)(iii) of the NYSE American Company Guide, citing stockholders' equity of $3.02 million (below the $4.0 million minimum) and losses in five consecutive fiscal years. While the company's plan to regain compliance was accepted with a deadline of October 2, 2027, the filing explicitly warns that \"if the Company does not regain compliance...then NYSE American staff may initiate delisting proceedings as appropriate.\" This is a material delisting risk event that would significantly affect investor assessment of the registrant's continued listing status.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-26T21:16:48.693418+00:00","company_name":"Matinas BioPharma Holdings, Inc.","ticker":"MTNB","filing_date":"2026-06-26"}]}